Literature DB >> 10197041

Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents.

Q Shi1, K Chen, S L Morris-Natschke, K H Lee.   

Abstract

Tubulin protein is a major target of drug molecules, and consequently, tubulin inhibitors have attracted great attention as antimitotic antitumor agents for chemotherapeutic use. Hundreds of synthetic or semisynthetic tubulin inhibitors have been discovered and developed recently that are related to the natural products colchicine, vinblastine, and taxol. Representatives include allothiocolchicinoids, vinorelbine, and taxotere. This review will describe the recent progress being made in the development of novel antimitotic antitumor tubulin inhibitors. The emphasis has been placed on related research in the author's laboratory, including development of colchicine derivatives and other colchicine binding site drugs, such as flavonoids and quinolone derivatives. Syntheses and modifications of novel compounds, biological activity evaluation, and structural activity relationships will be discussed as well. Further research will undoubtedly lead to the discovery of additional tubulin inhibitors that have potential for use as anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10197041

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  16 in total

1.  Microtubule stability studied by three-dimensional molecular theory of solvation.

Authors:  Piotr Drabik; Sergey Gusarov; Andriy Kovalenko
Journal:  Biophys J       Date:  2006-10-20       Impact factor: 4.033

2.  Linobiflavonoid inhibits human lung adenocarcinoma A549 cells: effect on tubulin protein.

Authors:  Dongbo Zhao; Guang Yang; Qingyang Meng; Junxing Liu; Shuang Yang
Journal:  Mol Biol Rep       Date:  2013-09-23       Impact factor: 2.316

3.  Inhibitory action of chamaejasmin A against human HEP-2 epithelial cells: effect on tubulin protein.

Authors:  Yan Zhao; Fenglian Wu; Yu Wang; Shengwu Chen; Guojun Han; Ming Liu; Dejun Jin
Journal:  Mol Biol Rep       Date:  2012-10-07       Impact factor: 2.316

4.  Anticancer activity and possible mode of action of 4-O-podophyllotoxinyl 12-hydroxyl-octadec-Z-9-enoate.

Authors:  Guoyi Ma; Shabana I Khan; Jamal Mustafa; Larry A Walker; Ikhlas A Khan
Journal:  Lipids       Date:  2005-03       Impact factor: 1.880

5.  Selective inhibition of human leukemia cell growth and induction of cell cycle arrest and apoptosis by pseudolaric acid B.

Authors:  Guoyi Ma; Li Chong; Xing-Cong Li; Ikhlas A Khan; Larry A Walker; Shabana I Khan
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-07       Impact factor: 4.553

6.  Synthesis, spectroscopic, and biological studies of novel estolides derived from anticancer active 4-O-podophyllotoxinyl 12-hydroxyl-octadec-Z-9-enoate.

Authors:  Jamal Mustafa; Shabana I Khan; Guoyi Ma; Larry A Walker; Ikhlas A Khan
Journal:  Lipids       Date:  2004-07       Impact factor: 1.880

7.  Slow polymerization of Mycobacterium tuberculosis FtsZ.

Authors:  E L White; L J Ross; R C Reynolds; L E Seitz; G D Moore; D W Borhani
Journal:  J Bacteriol       Date:  2000-07       Impact factor: 3.490

8.  Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents.

Authors:  M V Ramana Reddy; Muralidhar R Mallireddigari; Venkat R Pallela; Stephen C Cosenza; Vinay K Billa; Balaiah Akula; D R C Venkata Subbaiah; E Vijaya Bharathi; Amol Padgaonkar; Hua Lv; James M Gallo; E Premkumar Reddy
Journal:  J Med Chem       Date:  2013-06-25       Impact factor: 7.446

9.  Synthesis and structure-activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance protein.

Authors:  Hiteshkumar D Jain; Chunchun Zhang; Shuo Zhou; Hao Zhou; Jun Ma; Xiaoxiang Liu; Xuebin Liao; Amy M Deveau; Christine M Dieckhaus; Michael A Johnson; Kirsten S Smith; Timothy L Macdonald; Hideaki Kakeya; Hiroyuki Osada; James M Cook
Journal:  Bioorg Med Chem       Date:  2008-02-20       Impact factor: 3.641

10.  Securin enhances the anti-cancer effects of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075) in human colorectal cancer cells.

Authors:  Ho-Hsing Tseng; Qiu-Yu Chuah; Pei-Ming Yang; Chiung-Tong Chen; Jung-Chi Chao; Ming-Der Lin; Shu-Jun Chiu
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.